These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23664548)

  • 1. Blood pressure, proteinuria, and phosphate as risk factors for progressive kidney disease: a hypothesis.
    Cozzolino M; Gentile G; Mazzaferro S; Brancaccio D; Ruggenenti P; Remuzzi G
    Am J Kidney Dis; 2013 Nov; 62(5):984-92. PubMed ID: 23664548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD.
    Agarwal R
    Clin J Am Soc Nephrol; 2009 Sep; 4(9):1523-8. PubMed ID: 19478099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis.
    Gutiérrez OM
    Clin J Am Soc Nephrol; 2010 Sep; 5(9):1710-6. PubMed ID: 20507957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor 23--structure, function and role in kidney diseases.
    Kocełak P; Olszanecka-Glinianowicz M; Chudek J
    Adv Clin Exp Med; 2012; 21(3):391-401. PubMed ID: 23214203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into the role of fibroblast growth factor 23 in chronic kidney disease.
    Nakai K; Komaba H; Fukagawa M
    J Nephrol; 2010; 23(6):619-25. PubMed ID: 20658451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system.
    Prié D; Friedlander G
    Clin J Am Soc Nephrol; 2010 Sep; 5(9):1717-22. PubMed ID: 20798257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic kidney disease in long-term survivors of myeloablative allogeneic haematopoietic cell transplantation: prevalence and risk factors.
    Ando M; Ohashi K; Akiyama H; Sakamaki H; Morito T; Tsuchiya K; Nitta K
    Nephrol Dial Transplant; 2010 Jan; 25(1):278-82. PubMed ID: 19762604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology of calcium and phosphate metabolism impairment in chronic kidney disease.
    Cozzolino M; Ciceri P; Volpi EM; Olivi L; Messa PG
    Blood Purif; 2009; 27(4):338-44. PubMed ID: 19295196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should we shift toward higher blood pressure targets in patients with chronic kidney disease?
    Gentile G; Strippoli GF
    J Nephrol; 2011; 24(6):673-85. PubMed ID: 22058026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF23/Klotho axis: phosphorus, mineral metabolism and beyond.
    Donate-Correa J; Muros-de-Fuentes M; Mora-Fernández C; Navarro-González JF
    Cytokine Growth Factor Rev; 2012; 23(1-2):37-46. PubMed ID: 22360923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.
    Cunningham J; Locatelli F; Rodriguez M
    Clin J Am Soc Nephrol; 2011 Apr; 6(4):913-21. PubMed ID: 21454719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
    Stubbs J; Liu S; Quarles LD
    Semin Dial; 2007; 20(4):302-8. PubMed ID: 17635819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating α-klotho levels in CKD and relationship to progression.
    Kim HR; Nam BY; Kim DW; Kang MW; Han JH; Lee MJ; Shin DH; Doh FM; Koo HM; Ko KI; Kim CH; Oh HJ; Yoo TH; Kang SW; Han DS; Han SH
    Am J Kidney Dis; 2013 Jun; 61(6):899-909. PubMed ID: 23540260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications.
    Damasiewicz MJ; Toussaint ND; Polkinghorne KR
    Nephrology (Carlton); 2011 Mar; 16(3):261-8. PubMed ID: 21265930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients.
    Horio T; Iwashima Y; Kamide K; Tokudome T; Yoshihara F; Nakamura S; Kawano Y
    J Hypertens; 2010 Aug; 28(8):1738-44. PubMed ID: 20485194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What would we like to know, and what do we not know about fibroblast growth factor 23?
    Cozzolino M; Galassi A; Apetrii M; Covic A
    J Nephrol; 2011; 24(6):696-706. PubMed ID: 21786227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ; González EA
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of proteinuria: CKD progression and cardiovascular outcomes.
    Sarnak MJ; Astor BC
    Adv Chronic Kidney Dis; 2011 Jul; 18(4):258-66. PubMed ID: 21782132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chronic kidney disease (CKD) and bone. Chronic kidney disease--mineral and bone disorder in predialysis patients].
    Inaguma D; Tatematsu M
    Clin Calcium; 2009 Apr; 19(4):493-9. PubMed ID: 19329827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.